Effect of severity disease on the pharmacokinetics of cefuroxime in children with multiple organ system failure

Related Experiment Videos

Hugo Juárez Olguín1, Ismael Lares Asseff, Angélica Camacho Vieyra

  • 1Laboratorio de Farmacología, Instituto Nacional de Pediatría, Colonia Insurgentes Cuicuilco, Mexico City, Mexico.

Biological & Pharmaceutical Bulletin
|February 2, 2008
PubMed

Insights

The severity of illness significantly impacts cefuroxime pharmacokinetics in critically ill children. Understanding these cefuroxime (antibiotic) pharmacokinetic differences is key for personalized dosing in pediatric multiple organ system failure.

Area of Science:

  • Pediatric Pharmacology
  • Critical Care Medicine
  • Pharmacokinetics

Background:

  • Multiple organ system failure (MOSF) in children presents complex therapeutic challenges.
  • Antibiotic pharmacokinetics can be significantly altered in critically ill pediatric patients.
  • Cefuroxime is a commonly used antibiotic in pediatric critical care settings.

Purpose of the Study:

  • To investigate the influence of illness severity on cefuroxime pharmacokinetics in pediatric patients with MOSF.
  • To compare cefuroxime pharmacokinetic parameters across different severity groups (severely ill, very severely ill, and control).

Main Methods:

  • Pharmacokinetic analysis of cefuroxime in 11 pediatric patients with MOSF.
  • Patients categorized into three groups based on illness severity (Group 0: control, Group 1: severe, Group 2: very severe).
  • Plasma cefuroxime concentrations measured using High-Performance Liquid Chromatography (HPLC) after a standardized intravenous dose.

Main Results:

  • Cefuroxime exhibited one and two compartmental pharmacokinetic distribution models.
  • Significant differences in pharmacokinetic parameters were observed between severe (Group 1) and very severe (Group 2) illness groups.
  • Most pharmacokinetic parameters differed significantly between the ill groups (1 and 2) and the control group (0), with the exception of clearance between Group 1 and Group 0.

Conclusions:

  • Illness severity is a critical determinant of cefuroxime pharmacokinetics in pediatric patients with MOSF.
  • Observed pharmacokinetic variations necessitate individualized cefuroxime dosing strategies for pediatric patients.
  • Tailoring cefuroxime dosage based on disease severity can optimize therapeutic outcomes in critically ill children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...